Press Release: Novartis receives positive CHMP -2-

ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis

Novartis is reimagining medicine to improve and extend people's lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 108,000 people of more than 140 nationalities work at Novartis around the world. Find out more at https://www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at https://twitter.com/novartisnews https://twitter.com/novartisnews

For Novartis multimedia content, please visit https://www.novartis.com/news/media-library https://www.novartis.com/news/media-library

For questions about the site or required registration, please contact media.relations@novartis.com

References

1. Wolf J, Garon EB, Groen HJM, Tan DSW, Robeva A, Le Mouhaer S, et al.

Capmatinib in MET exon 14-mutated, advanced NSCLC: updated results from

the GEOMETRY mono-1 study. Poster presented at 2021 American Society of

Clinical Oncology (ASCO) Annual Meeting, June 4-8, Chicago, IL.

2. Novartis data on file.

3. Sadiq AA, Salgia R. MET as a possible target for non-small-cell lung

cancer. J Clin Oncol. 2013;31:1089.

4. Salgia R. MET in lung cancer: biomarker selection based on scientific

rationale. Mol Cancer Ther. 2017;16(4):555-565.

5. Novartis data on file.

6. Tong JH, et al. MET amplification and exon 14 splice site mutation define

unique molecular subgroups of non-small cell lung carcinoma with poor

prognosis. Clin Cancer Res. 2016;22:3048-3056.

7. Cappuzzo F, Marchetti A, Rossi E. Increased MET gene copy number

negatively affects survival of surgically resected non-small-cell lung

cancer patients. J Clin Oncol. 2009;27:1667-1674.

8. Smyth EC, et al. Emerging molecular targets in oncology: clinical

potential of MET/hepatocyte growth-factor inhibitors. Onco Targets Ther.

2014;7:1001-1014.

9. World Health Organization. Cancer. Available at:

https://www.who.int/news-room/fact-sheets/detail/cancer. Accessed March

21, 2022.

10. American Cancer Society. What is lung cancer? Available

at: https://www.cancer.org/cancer/lung-cancer/about/what-is.html

https://www.cancer.org/cancer/lung-cancer/about/what-is.html. Accessed

March 21, 2022.

# # #

Novartis Media Relations

E-mail: media.relations@novartis.com

Anja von Treskow Veronique Boissonnas

Novartis External Communications Global Oncology Communications, Solid Tumors

+41 61 324 2279 (direct) +1 646 872 3153 (mobile)

+41 79 392 8697 (mobile) veronique.boissonnas@novartis.com

anja.von_treskow@novartis.com

Julie Masow

Novartis US External Communications

+1 862 579 8456

julie.masow@novartis.com

Novartis Investor Relations

Central investor relations line: +41 61 324 7944

E-mail: investor.relations@novartis.com

Central North America

Samir Shah +41 61 324 7944 Sloan Simpson +1 862 345 4440

Nicole Zinsli-Somm +4 16 132 43809 Alina Levchuk +1 862 778 3372

Isabella Zinck +41 61 324 7188 Parag Mahanti +1 973-876-4912

(END) Dow Jones Newswires

April 22, 2022 09:27 ET (13:27 GMT)